LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics

By LabMedica International staff writers
Posted on 12 Nov 2018
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Image: The Atellica Solution immunoassay and clinical chemistry analyzers (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.

The analyzers are integrated with Atellica Diagnostics IT solutions and will connect to the company’s strategic partner Inpeco’s FlexLab track for total lab automation to deliver a high throughput multi-disciplinary solution with capabilities that are transforming the clinical laboratory landscape across Australia.

Siemens Healthineers offers a wide portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Primary Health Care has a large presence in all mainland states in Australia with one in every three pathology samples taken in the country being tested in a Primary laboratory. The Siemens Healthineers technology will be rolled out in New South Wales, Queensland, Victoria and Western Australia.

The strategic engagement couples Primary’s expansive network of more than 2,300 national pathology collection sites with workflow improvement and expanded clinical capabilities from Siemens Healthineers to establish a new level of automated diagnostic delivery. Through deep analytics, and intelligent data and process management, Atellica Diagnostics IT software will provide Primary with improved visibility, flexibility and control over its entire operation. Siemens Healthineers and Inpeco SA will deliver this fully automated multidisciplinary solution that will vastly simplify clinical and operational workflows and help Primary achieve better outcomes at much lower costs.

“With the introduction of the Atellica Solution and the complementary, innovative offering of Atellica Diagnostics IT, we’ll turn what has been more than a decade of collaboration with Primary Health Care into an entirely new frontier for the Australian pathology industry,” said Sebastian D’Angelo, General Manager, Laboratory Diagnostics, Australia, Siemens Healthineers.

“This new collaboration will allow us to take Primary’s operational efficiencies to new heights,” said Wes Lawrence, Chief Executive of Pathology at Primary Health Care. “Thanks to this next-generation technology, we’re able to increase productivity, and focus more on value-adding lab activities and less on sample and instrument handling. In doing so, processes will be reduced and testing quality will be advanced, ultimately helping us increase cost savings and focus on the human impact of our work.”

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more